sbfm
- Creatore Discussione axelvento
- Data di inizio
Management of Sunshine Biopharma Alarmed by the Recent World Health Organization Report That Cancer Is on the Rise
Date : 03/31/2014 @ 8:00AM
Source : Marketwired
Stock : Sunshine Biopharma Inc. (QB) (SBFM)
Quote : 0.175 0.0201 (12.98%) @ 12:15AM
Management of Sunshine Biopharma Alarmed by the Recent World Health Organization Report That Cancer Is on the Rise
Print
Alert
Sunshine Biopharma Inc. (QB) (USOTC:SBFM)
Historical Stock Chart
1 Month : From Mar 2014 to Apr 2014
Management of Sunshine Biopharma Alarmed by the Recent World Health Organization Report That Cancer Is on the Rise
MONTREAL, QC--(Marketwired - Mar 31, 2014) - Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, has issued a response to the recently released reports by the World Health Organization and the Pancreatic Cancer Action Network.
According to "World Cancer Report 2014" issued in February by the World Health Organization, cancer is on the rise and has become a leading cause of death worldwide, accounting for 8.2 million deaths in 2012. Lung cancer accounted for 1.59 million deaths and breast cancer represented half a million deaths. The report also says that cancer cases are expected to rise significantly: "It is expected that annual cancer cases will rise from 14 million in 2012 to 22 million within the next two decades."
Additionally the Pancreatic Cancer Action Network released a special report entitled "The Alarming Rise of Pancreatic Cancer Deaths in the United States: Why We Need to Stem the Tide Today." The report noted that "(t)he alarming findings presented in the report include the fact that by the year 2020, and possibly as early as 2015, pancreatic cancer will move from the fourth leading cause of cancer death to the second leading cause of cancer death in the United States."
"We are alarmed and impassioned by these trends to move vigorously ahead with our clinical development of Adva-27a for aggressive forms of cancer," said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "The Company is planning a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant breast cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada)."
Sunshine Biopharma recently reported that it has initiated the construction of mouse xenograft models for pancreatic cancer as part of the plans of positioning Adva-27a for clinical development for pancreatic cancer in parallel with multidrug resistant breast cancer. Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly
CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.co
Date : 03/31/2014 @ 8:00AM
Source : Marketwired
Stock : Sunshine Biopharma Inc. (QB) (SBFM)
Quote : 0.175 0.0201 (12.98%) @ 12:15AM
Management of Sunshine Biopharma Alarmed by the Recent World Health Organization Report That Cancer Is on the Rise
Alert
Sunshine Biopharma Inc. (QB) (USOTC:SBFM)
Historical Stock Chart
1 Month : From Mar 2014 to Apr 2014
Management of Sunshine Biopharma Alarmed by the Recent World Health Organization Report That Cancer Is on the Rise
MONTREAL, QC--(Marketwired - Mar 31, 2014) - Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, has issued a response to the recently released reports by the World Health Organization and the Pancreatic Cancer Action Network.
According to "World Cancer Report 2014" issued in February by the World Health Organization, cancer is on the rise and has become a leading cause of death worldwide, accounting for 8.2 million deaths in 2012. Lung cancer accounted for 1.59 million deaths and breast cancer represented half a million deaths. The report also says that cancer cases are expected to rise significantly: "It is expected that annual cancer cases will rise from 14 million in 2012 to 22 million within the next two decades."
Additionally the Pancreatic Cancer Action Network released a special report entitled "The Alarming Rise of Pancreatic Cancer Deaths in the United States: Why We Need to Stem the Tide Today." The report noted that "(t)he alarming findings presented in the report include the fact that by the year 2020, and possibly as early as 2015, pancreatic cancer will move from the fourth leading cause of cancer death to the second leading cause of cancer death in the United States."
"We are alarmed and impassioned by these trends to move vigorously ahead with our clinical development of Adva-27a for aggressive forms of cancer," said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "The Company is planning a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant breast cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada)."
Sunshine Biopharma recently reported that it has initiated the construction of mouse xenograft models for pancreatic cancer as part of the plans of positioning Adva-27a for clinical development for pancreatic cancer in parallel with multidrug resistant breast cancer. Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly
CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.co
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
news:
Sunshine Biopharma Increases the Effectiveness of Adva-27a Lead Compound 9.5-Fold Against Breast and Pancreatic Cancer in Vitro
Sunshine Biopharma
Today : Monday 7 April 2014
Click Here for more Sunshine Biopharma Inc.
Sunshine Biopharma Increases the Effectiveness of Adva-27a Lead Compound 9.5-Fold Against Breast and Pancreatic Cancer in Vitro
MONTREAL, QC--(Marketwired - Apr 7, 2014) - Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer today announced that it has resolved the two isomeric forms of its lead anticancer compound, Adva-27a, and as a result the specific activity of the drug candidate has increased 9.5-fold. Sunshine Biopharma had previously announced that the concentration at which Adva-27a inhibited 50% of the activity of Topoisomerase II (IC50) was 13.7 micromolar (see press release issued on October 5, 2011). As a result of today's development Adva-27a's IC50 has dropped 9.5-fold, to 1.44 micromolar. This implies that significantly lower quantities of the drug can be used to achieve the same effect.
"Isomeric forms of a compound refer to the fact that the compound has different arrangements of its atoms in space," said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "Isomeric forms do not have identical properties. In the case of Adva-27a, the molecule exists in the alpha or beta form. This is a lot like a person's left hand and right hand. While the two hands look identical, they actually are not. They are mirror images of each other but are not superimposable. The fact that they are not superimposable means that they are not identical. Similarly, the alpha and beta forms of Adva-27a are not superimposable. The implications of all of this for our future breast cancer and pancreatic cancer patients are lower therapeutic dosages, which theoretically should result in reduced side-effects."
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935. The Company is planning a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant breast cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly
CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
Sunshine Biopharma | Sunshine Biopharma is focused on the research, development and commercialization of drugs for the treatment of various forms of cancer.
Sunshine Biopharma Increases the Effectiveness of Adva-27a Lead Compound 9.5-Fold Against Breast and Pancreatic Cancer in Vitro
Sunshine Biopharma
Today : Monday 7 April 2014
Click Here for more Sunshine Biopharma Inc.
Sunshine Biopharma Increases the Effectiveness of Adva-27a Lead Compound 9.5-Fold Against Breast and Pancreatic Cancer in Vitro
MONTREAL, QC--(Marketwired - Apr 7, 2014) - Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer today announced that it has resolved the two isomeric forms of its lead anticancer compound, Adva-27a, and as a result the specific activity of the drug candidate has increased 9.5-fold. Sunshine Biopharma had previously announced that the concentration at which Adva-27a inhibited 50% of the activity of Topoisomerase II (IC50) was 13.7 micromolar (see press release issued on October 5, 2011). As a result of today's development Adva-27a's IC50 has dropped 9.5-fold, to 1.44 micromolar. This implies that significantly lower quantities of the drug can be used to achieve the same effect.
"Isomeric forms of a compound refer to the fact that the compound has different arrangements of its atoms in space," said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "Isomeric forms do not have identical properties. In the case of Adva-27a, the molecule exists in the alpha or beta form. This is a lot like a person's left hand and right hand. While the two hands look identical, they actually are not. They are mirror images of each other but are not superimposable. The fact that they are not superimposable means that they are not identical. Similarly, the alpha and beta forms of Adva-27a are not superimposable. The implications of all of this for our future breast cancer and pancreatic cancer patients are lower therapeutic dosages, which theoretically should result in reduced side-effects."
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935. The Company is planning a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant breast cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly
CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
Sunshine Biopharma | Sunshine Biopharma is focused on the research, development and commercialization of drugs for the treatment of various forms of cancer.
visal
In cul@ al nasdaq
- Registrato
- 20/6/01
- Messaggi
- 23.858
- Punti reazioni
- 304
Barriera a 0.24$
Allegati
visal
In cul@ al nasdaq
- Registrato
- 20/6/01
- Messaggi
- 23.858
- Punti reazioni
- 304
fred perry
Uschione
- Registrato
- 12/7/05
- Messaggi
- 8.190
- Punti reazioni
- 709
dopo il mini rialzo di aprile, è tornata nell' oblio. nel breve potrebbe ritornare a toccare il supporto a 0,13. 
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
Sunshine Biopharma Negotiating With CRO's to Initiate Master Drug File for Adva-27a Anticancer Compound
MONTREAL, QC - Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is currently negotiating with several Contract Research Organizations (CRO's) with the intent to engage one of them for the purposes of initiating, compiling and managing a regulatory master drug file for Adva-27a, the Company's flagship anticancer compound. A master drug file contains all of the information that regulatory agencies require as part of the drug development and approval process. Such information includes preclinical data, GMP manufacturing process, large animal studies and human trials.
"Engaging a CRO is the next step in our Adva-27a drug development program," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "We are delighted to have arrived at this advanced stage in the development of our Adva-27a. The CRO will compile the testing results conducted to date, follow and document the GMP manufacturing process, manage the large animal studies and file with the appropriate regulatory agencies for go-ahead with Phase I human trials."
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935. The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly
CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
Sunshine Biopharma | Sunshine Biopharma is focused on the research, development and commercialization of drugs for the treatment of various forms of cancer.
tutta roba mia...
$ 0,075 11,700 OTO 09:49:09
$ 0,0771 10,000 OTO 09:49:07
$ 0,0771 13,000 OTO 09:45:46
$ 0,0771 10,000 OTO 09:45:38
$ 0,0771 10,000 OTO 09:44:48
$ 0,075 10,000 OTO 10:17:14
$ 0,075 10,000 OTO 10:15:59
$ 0,0775 5,000 OTO 10:10:25
MONTREAL, QC - Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is currently negotiating with several Contract Research Organizations (CRO's) with the intent to engage one of them for the purposes of initiating, compiling and managing a regulatory master drug file for Adva-27a, the Company's flagship anticancer compound. A master drug file contains all of the information that regulatory agencies require as part of the drug development and approval process. Such information includes preclinical data, GMP manufacturing process, large animal studies and human trials.
"Engaging a CRO is the next step in our Adva-27a drug development program," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "We are delighted to have arrived at this advanced stage in the development of our Adva-27a. The CRO will compile the testing results conducted to date, follow and document the GMP manufacturing process, manage the large animal studies and file with the appropriate regulatory agencies for go-ahead with Phase I human trials."
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935. The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly
CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
Sunshine Biopharma | Sunshine Biopharma is focused on the research, development and commercialization of drugs for the treatment of various forms of cancer.
tutta roba mia...
$ 0,075 11,700 OTO 09:49:09
$ 0,0771 10,000 OTO 09:49:07
$ 0,0771 13,000 OTO 09:45:46
$ 0,0771 10,000 OTO 09:45:38
$ 0,0771 10,000 OTO 09:44:48
$ 0,075 10,000 OTO 10:17:14
$ 0,075 10,000 OTO 10:15:59
$ 0,0775 5,000 OTO 10:10:25
fred perry
Uschione
- Registrato
- 12/7/05
- Messaggi
- 8.190
- Punti reazioni
- 709
AXEL, come mai questa discesa odierna con volumi ? non leggo news drammatiche o super negative ?
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
Sunshine Biopharma Announces That Its Breast Cancer Drug Candidate, Adva-27a, Also Destroys Pancreatic Cancer Cells - MarketWatch
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935. The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
di solito il treno passa una volta sola.....
e quindi è meglio salire...
comprare quando nessuno le vuole
piu o meno la struttura è questa
Shares Outstanding 68,270,961 a/o Aug 12, 2014
Float 13,916,529 a/o Mar 15, 2012
Authorized Shares 200,000,000 a/o Dec 31, 2011
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935. The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
di solito il treno passa una volta sola.....
e quindi è meglio salire...
comprare quando nessuno le vuole
piu o meno la struttura è questa
Shares Outstanding 68,270,961 a/o Aug 12, 2014
Float 13,916,529 a/o Mar 15, 2012
Authorized Shares 200,000,000 a/o Dec 31, 2011
Allegati
fred perry
Uschione
- Registrato
- 12/7/05
- Messaggi
- 8.190
- Punti reazioni
- 709
scrollano le mani deboli..
per me è stato tempo di saldi
stai sgranocchiando anche oggi ?
0,06-0,07...
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
fred perry
Uschione
- Registrato
- 12/7/05
- Messaggi
- 8.190
- Punti reazioni
- 709
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419